Clinical trials: Cystic Fibrosis - Complete
Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups.
- Trial name
- NCT03251092
- Testing
- PTI-808, PTI-428, PTI-801
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Proteostasis Therapeutics, Inc.
Long-term Safety of TIP
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
The purpose of this extension study is to collect additional 48 weeks of safety data from patients taking TIP who have completed the core study CTBM100C2401.
- Trial name
- NCT01775137
- Testing
- TBM100
- Where
- 21 sites in United States, Argentina and 7 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Infections, Pseudomonas Aeruginosa
Second Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were…
- Trial name
- NCT01069705
- Testing
- Tobramycin inhalation powder
- Where
- 17 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Pseudomonas Aeruginosa, Cystic Fibrosis
Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas…
- Trial name
- NCT00982930
- Testing
- Tobramycin inhalation powder
- Where
- 2 sites in Estonia, Russia
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals